Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemafibrate ER in dyslipidemia with high triglycerides
NCT04716595Phase 3Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- Feb 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pemafibrate in dyslipidemia (2 arms), sponsored by Kowa Company, Ltd. Primary endpoint: Fasting Serum Triglycerides at 52 weeks. Started Feb 2021; status: completed.
02
Drugs
pemafibrate
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT04716595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04716595.